Author

J. Lilja

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. Ivaska· 3 shared E. Peuhu· 2 shared G. Jacquemet· 2 shared I. Vattulainen· 2 shared J. Vuorio· 2 shared A. Isomursu· 1 shared A. K. Najumudeen· 1 shared D. Abankwa· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Ivaska

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting a broad spectrum of KRAS-mutant cancers by hyperactivation-induced cell death

J. Lilja, J. Kaivola, J. R. W. Conway, J. Vuorio, H. Parkkola, P. Roivas, T. Varila, G. Jacquemet, E. Peuhu, E. Wang, U. Pentikäinen, I. M. D. Posada, H. Hamidi, A. K. Najumudeen, O. J. Sansom, , J. Ivaska

This study identifies SHANK3 as a RAS interactor that limits oncogenic KRAS signaling, and shows that disrupting its interaction with KRAS induces cell death in KRAS-mutant cancers.

bioRxiv · Sep 21, 2022 · PreprintCancer Biology

Sortilin-related receptor is a druggable therapeutic target in breast cancer

H. Al-Akhrass, M. Pietilä, J. Lilja, E.-M. Vesilahti, J. M. Anttila, H. M. Haikala, P. M. Munne, J. Klefström, E. Peuhu, J. Ivaska

This study shows that targeting SorLA with a monoclonal antibody can overcome HER2 resistance in breast cancer, both in vitro and in vivo.

bioRxiv · Mar 9, 2021Cancer Biology

Conformational dynamics regulate SHANK3 actin and Rap1 binding

S. I. Salomaa, M. Miihkinen, E. Kremneva, I. Paatero, J. Lilja, G. Jacquemet, J. Vuorio, L. Antenucci, F. Hassani-Nia, P. Hollos, A. Isomursu, I. Vattulainen, E. T. Coffey, H.-J. Kreienkamp, P. Lappalainen, J. Ivaska

This study shows SHANK3 binds actin and Rap1 through its SPN domain, with conformational changes regulating this interaction and affecting cellular processes like filopodia formation and autism-related phenotypes.

bioRxiv · Nov 12, 2020 · PreprintCell Biology